Masimo Co. (NASDAQ:MASI) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Masimo Co. (NASDAQ:MASI) have received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $144.67.

Several research firms have recently commented on MASI. Piper Sandler lifted their price target on shares of Masimo from $160.00 to $165.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research note on Friday, September 20th.

Masimo Stock Up 0.1 %

NASDAQ:MASI opened at $133.20 on Monday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.15 and a current ratio of 2.09. The company has a market capitalization of $7.08 billion, a price-to-earnings ratio of 90.61 and a beta of 0.98. Masimo has a one year low of $75.22 and a one year high of $153.93. The stock has a 50-day simple moving average of $116.67 and a 200 day simple moving average of $124.97.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.09. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The business had revenue of $496.30 million during the quarter, compared to the consensus estimate of $493.92 million. During the same period in the previous year, the business earned $0.62 EPS. The business’s quarterly revenue was up 9.0% on a year-over-year basis. Sell-side analysts predict that Masimo will post 3.87 EPS for the current fiscal year.

Institutional Investors Weigh In On Masimo

Several large investors have recently made changes to their positions in MASI. Riverview Trust Co acquired a new position in shares of Masimo during the first quarter worth approximately $25,000. GAMMA Investing LLC boosted its position in Masimo by 75.0% during the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 111 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of Masimo by 851.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 295 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 264 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Masimo by 133.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 200 shares during the period. Finally, Parallel Advisors LLC raised its stake in shares of Masimo by 48.3% during the fourth quarter. Parallel Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $52,000 after purchasing an additional 145 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.